Get started
Author

Olaf Pirk

Observed names: O PIRK, O Pirk, O. Pirk, Pirk, Olaf, Pirk, Olaf 1962-
OpenAlex ID: A5034924669
Irritable bowel syndrome in Germany. A cost of illness study
2002 · Stefan A Müller-Lissner, Olaf Pirk · European Journal of Gastroenterology & Hepatology · 60
Diffusion of innovations: treatment of Alzheimer's disease in Germany
2002 · Jörg Ruof, Thomas Mittendorf, et al. · Health Policy · 40
The value of irbesartan in the management of hypertension
2009 · Peter Bramlage, Isabelle Durand-Zaleski, et al. · Expert Opinion on Pharmacotherapy · 33
Dementia care initiative in primary practice – study protocol of a cluster randomized trial on dementia management in a general practice setting
2009 · Rolf Holle, Elmar Gräßel, et al. · BMC Health Services Research · 30
PDF
Therapie der Alzheimer-Demenz mit der besten verfügbaren Evidenz - eine Utopie?
2005 · G Stoppe, O Pirk, et al. · Das Gesundheitswesen · 14
Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy
2010 · J. Mathes, K. Kostev, et al. · International Journal of Clinical Pharmacology and Therapeutics · 12
A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
2007 · Wioletta Kotowa, Ulrich Gatzemeier, et al. · Journal of Medical Economics · 12
PDF
BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
2016 · William C. N. Dunlop, C. Daniel Mullins, et al. · PharmacoEconomics · 11
PDF
Kosten für antihyperglykämische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes
2009 · H Hauner, T Kohlmann, et al. · DMW - Deutsche Medizinische Wochenschrift · 9
Pcv108 Risk and Costs of the First Hypertension-associated Event, Compliance and Persistence in Naïve Hypertensive Patients After Initiating Monotherapy
2008 · J Mathes, K Kostev, et al. · Value in Health · 5
Preisbildung und Erstattung
2008 · Olaf Pirk · Springer eBooks · 5
The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain Studies
2015 · Catherine E. Rycroft, Matthew Hirst, et al. · Value in Health · 4
PDF
1 Primärdatenerhebung
2011 · Olaf Pirk, Oliver Schöffski · Springer eBooks · 4
Second-Line-Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) – eine retrospektive Kostenanalyse
2008 · U Gatzemeier, O Pirk, et al. · TumorDiagnostik & Therapie · 4
Cn1 a Stochastic Economic Evaluation of Letrozole Versus Tamoxifen as a First-line Hormonal Therapy for Advanced Breast Cancer in Postmenopausal Patients in Germany
2002 · FU Fricke, K Quednau, et al. · Value in Health · 3
Pdb34 Lower Long-term Costs in German Type-2-diabetics Starting a Basal Supported Oral Therapy (bot) With Insulin Glargine Compared to Nph-insulin
2009 · W Kotowa, A Reichelt, et al. · Value in Health · 2
Comment and Reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
2008 · Jorge Arellano, Claudia Leteneux, et al. · Journal of Medical Economics · 2
PDF
Pcv26 Cost-effectiveness of Candesartan in Germany for Patients With Chronic Heart Failure
2005 · M Voelkl, O Pirk, et al. · Value in Health · 2
Einsparpotentiale in der Therapie hypertoner Typ-2-Diabetiker aufgrund verzögerter terminaler Niereninsuffizienz
2004 · Klaus-Peter Ratzmann, Olaf Pirk, et al. · PharmacoEconomics German Research Articles · 2
Das Design einer gesundheitsökonomischen Studie
2002 · O. Schöffski, C. Claes, et al. · Springer eBooks · 2
Pcv31 Long-term Cost-effectiveness of Rimonabant in Germany
2007 · O Pirk, F Hessel, et al. · Value in Health · 1
PDF
Pcv22 Case-based-costing Vs. Markov-modelling—a Comparison of Cost-effectiveness-analyses for Candesartan in Patients With Chronic Heart Failure
2005 · M Voelkl, O Pirk, et al. · Value in Health · 1
PDF
The lower the quality of life the higher health care costs in irritable Bowel syndrome
2001 · P ENCK, P ILGENSTEIN, et al. · Gastroenterology · 1
Stellungnahmeverfahren und Anhörung im G-BA
2020 · Olaf Pirk · Springer eBooks
Pns284 Is There a Need for Real World Evidence (rwe) in Health Technology Assessments of Rare Diseases and Oncology Treatments?
2019 · A. Forsythe, D. Tomaras, et al. · Value in Health
PDF
Works count: 47
Citation count: 259
H-index: 9
I10-index: 8
Year
Topic
Type